Monday, June 16, 1997
New U.K. investment trust
Reabourne was formed in 1995 as a joint venture to invest in life sciences companies in the U.K. and Western Europe, with a focus on biotechnology. Reabourne director Peter Keen co-founded Chiroscience Group plc (LSE:CRO) in 1990 with Chris Evans, who co-founded the Merlin Fund in 1996. Another Reabourne director, John Gordon, spent nine years at British Biotech plc (BBIOY) as the company's research director and served as CEO of BBIOY's Neures Ltd. subsidiary.
CASDIN THE BUYSIDER: Jeffrey Casdin is making select investments with his new investment vehicle, Casdin Life Science Partners. Since the fund closed in late February, Casdin has invested in two private deals. Last week, he participated in a $6.5 million private round for NetGenics, a bioinformatics software provider (see B16). Casdin also has participated in a financing round for CuraGen, a privately held functional genomics company.